HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Allergan plc

Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds

Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

Financing Deals

FTC May Go After Pharma Bundling, Rebates, Patent Processes With Reactivation of Section 5

Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.

Enforcement Legal Issues

Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s

Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.

Biosimilars Companies

Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Actavis, Inc.
    • Actavis plc
    • Akarna Therapeutics Ltd.
    • Allergan Aesthetics
    • Allergan, Inc.
    • Anterios, Inc.
    • Arrow Group (Subsidiaries: Arrow Generics (U.K), Cobalt Group (U.S.))
    • AqueSys, Inc.
    • Bonti, Inc.
    • Chase Pharmaceuticals Corporation, Inc.
    • Durata Therapeutics
    • Elastagen Pty Ltd
    • EndoArt SA
    • Envy Medical, Inc.
    • Forest Laboratories [Aptalis Pharmaceutical Technologies
    • (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.]
    • Furiex Pharmaceuticals, Inc. (PPD, Inc.)
    • Kythera Biopharmaceuticals, Inc.
    • MAP Pharmaceuticals
    • Motus Therapeutics, Inc. (Rhythm Health, Inc.)
    • Naurex, Inc.
    • Oculeve
    • Regado Biosciences, Inc.
    • RetroSense Therapeutics, LLC
    • Silom Medical Company
    • Uteron Pharma SA
    • Warner Chilcott PLC (Galen Holdings PLC)
    • Watson Pharmaceuticals, Inc.
    • Tobira Therapeutics, Inc.
    • Topokine Therapeutics
    • Vitae Pharmaceuticals, Inc.
    • ForSight VISION5, Inc.
    • LifeCell Corporation
    • ZELTIQ Aesthetics, Inc.
    • Zonagen, Inc.
    • Repros Therapeutics, Inc.
UsernamePublicRestriction

Register